

## **Heel Sponsors Hans-Heinrich Reckeweg Award**

**Award winners for research studies in complementary medicine: Dr. Hernán Silván and Dr. Oxana Kirgizova**

**Baden-Baden (Germany) – The Hans-Heinrich Reckeweg Award was presented Saturday on the occasion of the largest European conference on complementary medicine. Sponsored by Heel, a world leader in manufacturing homoeopathic medicinal products, the Award honours outstanding achievements in research into Homotoxicology and Bioregulation. This year's winner of the Main Award – which comes with a cash prize of 10,000 Euros – is Dr. Hernán Silván García, a sports medicine specialist from Spain. The Heel-funded 5,000-Euro Incentive Award went to Dr. Oxana Kirgizova in support of this Russian doctor's clinical study in paediatric medicine.**

Europe's largest conference on complementary medicine, the 'Medical Week', is held in Baden-Baden, Germany, from 29 October to 3 November 2010. Here, more than 4,000 medical professionals from many different disciplines have been comparing notes under the motto of 'Complementary Medicine – Success Through Synergies'. The focus of this year's event is on new approaches and research results expected to improve patient's treatments.

The annual Hans-Heinrich Reckeweg Award honors outstanding research into Bioregulation and Homotoxicology, a field of medicine established by Hans-Heinrich Reckeweg. Both the Main Award and the Incentive Award are sponsored by Heel. The award ceremony took place on 30 October in the Kurhaus Baden-Baden. Several hundred medical practitioners from all over the world applauded the winners who had presented their scientific work as part of the Symposium of the International Society of Homotoxicology and Homeopathy (ISOHH).

Dr. Hernán Silván, a sports medicine specialist from Spain, was this year's recipient of the 10,000-Euro Main Award for his excellent

research study in marathon runners with 'piriformis syndrome', a difficult-to-treat irritation of the sciatic nerve. Dr. Silván studied the efficacy of Traumeel injections as an adjunct to standard therapy versus only standard therapy. The jury praised his research as an outstanding example of a particularly well-designed and carefully conducted and documented clinical trial.

Dr. Silván treated 31 runners with routine treatment, whilst another 31 runners additionally received weekly shots of Traumeel into the skin (intradermal injections) near the insertion of the piriformis muscle. Outcomes in the two groups were compared by looking at patient-reported changes in pain perception and doing objective orthopaedic tests. The 10-week study suggested that Traumeel injections may improve standard treatment outcomes and speed up recovery.

The 5,000-Euro 2010 Sponsorship Award went to Dr. Oxana Kirgizova, a Russian specialist in paediatrics and adolescent medicine. She conducted a clinical trial to evaluate the efficacy of anti-homotoxic preparations in the management of dysfunctions of the hypothalamic-pituitary-ovarian-adrenal axis in young girls. Disruptions of this hormonal feedback loop may cause headaches and menstrual pain and even metabolic disorders.

Dr. Kirgizova subcutaneously (under the skin) injected 40 subjects with anti-homotoxic preparations at selected acupuncture points; another 40 girls received routine treatment and 40 subjects were treated by acupuncture. The observed changes in symptoms as well as objective tests including assessments based on electroencephalographic (EEG) recordings and blood tests, showed that anti-homotoxic preparations injected into acupuncture points were more effective than both classical acupuncture and standard care.

*Heel is an internationally operating company that develops, produces and markets homoeopathic combination remedies. In 2009, Biologische Heilmittel Heel GmbH, headquartered in Baden-Baden, Germany, had 1,300 employees and posted sales worth 173m Euros – 70 percent in markets outside Germany. Heel operates subsidiaries in Belgium, Brazil, Chile, Canada, Colombia, the Netherlands, Poland, Spain, the Republic of South Africa and the USA. Heel products are available in a total of 56 countries across the globe through various distribution partners.*

[www.heel.de](http://www.heel.de) / [www.heel.com](http://www.heel.com)

513 words, 3,663 characters (incl. blanks)



Photo 1: Presentation of the Hans-Heinrich Reckeweg Award 2010: (from left to right): Ralph Schmidt, CEO of Biologische Heilmittel Heel, Dr. Hernán Silván (Spain, winner of the Main Award), Dr. Oxana Kirgizova (Russia, winner of the Incentive Award), Dr. Alta Smit, Director Medical Affairs and Research at Heel, Dr. Robbert van Haselen, Head of Research at Heel.



Photo 2: Dr. Hernán Silván (Spain, winner of the Main Award) with Robbert van Haselen, Head of Research at Heel at the presentation of the Hans-Heinrich Reckeweg Award 2010.



Photo 3: Dr. Oxana Kirgizova (Russia, winner of the Incentive Award) and Dr. Alta Smit, Director Medical Affairs and Research at Heel, at the presentation of the Hans-Heinrich Reckeweg Award 2010.

Download photo in printable quality:

<http://www.oha-communication.com/en/heel/368-reckeweg-award-2010.html>

**Media contact:**

Biologische Heilmittel Heel GmbH

Matthias Reinig

Head of Corporate Communications

Phone: +49 7221 501-276

Fax: +49 7221 501-480

Email: [reinig.matthias@heel.de](mailto:reinig.matthias@heel.de)

Internet: [www.heel.de](http://www.heel.de) / [www.heel.com](http://www.heel.com)